Aldeyra Therapeutics (ALDX) Other Working Capital Changes (2013 - 2026)

Aldeyra Therapeutics (ALDX) has reported Other Working Capital Changes for 14 consecutive years, with $1.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Working Capital Changes rose 322.26% year-over-year to $1.0 million; the trailing twelve-month figure through Jun 2026 stood at $76272.0 (up 102.46% YoY), and the FY2025 full-year result was -$1.2 million, up 42.94% from the prior year.
• Other Working Capital Changes rose to $1.0 million in Q2 2026 per ALDX's latest filing, from -$470688.0 in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $2.8 million in Q1 2024 and bottomed at -$3.7 million in Q1 2023.
• Historically, Other Working Capital Changes has averaged -$37370.1 across 5 years, with a median of -$150330.0 in 2025.
• The sharpest annual moves came in 2024 and 2026: Other Working Capital Changes tumbled 1974.1% in 2024, then soared 322.26% in 2026.
• Over 5 years, Other Working Capital Changes stood at $2.6 million in 2022, then tumbled by 56.7% to $1.1 million in 2023, then sank by 194.89% to -$1.1 million in 2024, then surged by 60.16% to -$420494.0 in 2025, then surged by 342.0% to $1.0 million in 2026.
• According to Business Quant data, Other Working Capital Changes over the past three periods registered $1.0 million, -$470688.0, and -$420494.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.